Have a feature idea you'd love to see implemented?
Let us know!
INSM INSMED Inc
Price (delayed)
$70.78
Market cap
$12.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.39
Enterprise value
$12.29B
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved
Highlights
The equity has soared by 125% YoY and by 108% from the previous quarter
INSM's revenue is up by 22% year-on-year and by 4.2% since the previous quarter
The company's quick ratio has surged by 64% QoQ but it fell by 47% YoY
INSMED's net income has decreased by 15% YoY and by 7% QoQ
The EPS has declined by 3.1% since the previous quarter and by 2.3% year-on-year
Key stats
What are the main financial stats of INSM
Market
Valuations
Earnings
Shares outstanding
171.85M
Market cap
$12.16B
Enterprise value
$12.29B
Price to earnings (P/E)
N/A
Price to book (P/B)
270.96
Price to sales (P/S)
33.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.41
Revenue
$328.61M
EBIT
-$716.34M
EBITDA
-$701.78M
Free cash flow
-$590.61M
Per share
Balance sheet
Liquidity
EPS
-$5.39
Free cash flow per share
-$3.82
Book value per share
$0.26
Revenue per share
$2.12
TBVPS
$10.43
Total assets
$1.81B
Total liabilities
$1.77B
Debt
$1.38B
Equity
$38.82M
Working capital
$894.03M
Debt to equity
35.44
Current ratio
2.71
Quick ratio
2.46
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-213.6%
Gross margin
77.6%
Net margin
-244.3%
Operating margin
-231.4%
Return on assets
-57.1%
Return on equity
N/A
Return on invested capital
-47%
Return on capital employed
-55.7%
Return on sales
-218%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INSM stock price
How has the INSMED stock price performed over time
Intraday
-0.24%
1 week
-1.61%
1 month
-3.04%
1 year
197.39%
YTD
128.4%
QTD
-3.04%
Financial performance
How have INSMED's revenue and profit performed over time
Revenue
$328.61M
Gross profit
$255.04M
Operating income
-$760.35M
Net income
-$802.69M
Gross margin
77.6%
Net margin
-244.3%
INSM's revenue is up by 22% year-on-year and by 4.2% since the previous quarter
The company's gross profit rose by 20% YoY and by 3.5% QoQ
INSMED's net income has decreased by 15% YoY and by 7% QoQ
INSMED's operating income has decreased by 15% YoY and by 8% QoQ
Growth
What is INSMED's growth rate over time
Valuation
What is INSMED stock price valuation
P/E
N/A
P/B
270.96
P/S
33.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.41
The EPS has declined by 3.1% since the previous quarter and by 2.3% year-on-year
The equity has soared by 125% YoY and by 108% from the previous quarter
INSM's price to sales (P/S) is 118% higher than its 5-year quarterly average of 15.3 and 87% higher than its last 4 quarters average of 17.9
INSM's revenue is up by 22% year-on-year and by 4.2% since the previous quarter
Efficiency
How efficient is INSMED business performance
The ROIC has declined by 18% since the previous quarter and by 8% year-on-year
The company's return on assets fell by 15% YoY
The ROS has grown by 7% year-on-year but it has declined by 4% since the previous quarter
Dividends
What is INSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INSM.
Financial health
How did INSMED financials performed over time
INSM's total assets is 2.2% higher than its total liabilities
The company's quick ratio has surged by 64% QoQ but it fell by 47% YoY
INSM's total assets has soared by 56% QoQ and by 26% YoY
The equity has soared by 125% YoY and by 108% from the previous quarter
The debt has grown by 2.7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.